← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
AntibodyCRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 44%임상시험 84상태 RECRUITING
ADCSBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
AntibodyARocheGovitecanPhase 3

carboplatin-etoposide (Atezolizumab + chemotherapy, Atezolizumab + chemotherapy (carboplatin-etoposide))

Extensive Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Cancer

#ExtensiveStageSmallCellLungCance#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 83상태 RECRUITING
AntibodyCAmgenPhase 3

Blinatumomab (Blinatumomab)

B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#Antibody#Phase3#인기#항체+5
효능 ORR 11.1%임상시험 83상태 RECRUITING
AntibodyAAmgenPhase 3

Panitumumab (Panitumumab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 83상태 RECRUITING
ADCSBiologicRochederuxtecan (Dato-DXd, Datro…Phase 3

T-DXd (Trastuzumab-Deruxtecan, Trastuzumab-Deruxtecan (T-DXd))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 79.7%임상시험 83상태 RECRUITING
ADCCBiologicChristopher StrousePhase 2

Sirolimus (Sirolimus)

Multiple Myeloma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 9%임상시험 81상태 DISCONTINUED
AntibodyARochederuxtecan (Dato-DXd, Datro…Phase 3

Herceptin (Trastuzumab, Trastuzumab (Herceptin))

Breast Neoplasm, Exercise · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.2%임상시험 80상태 RECRUITING
ADCCBiologicShanghai Hansoh Biomedical Co.,…GQ1001Phase 1

Phase Ia: Dose escalation (HS-20093, HS-20093 (Phase Ia: Dose escalation))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#인기#항체약물접합체+4
임상시험 79상태 ACTIVE
ADCCBiologicGroupe d'Etude Therapeutique de…Approved

Mercaptopurine (Mercaptopurine)

Crohn's Disease · Leukemia

#Leukemia#ADC#Approved#인기#항체약물접합체+4
효능 ORR 22%임상시험 79상태 RECRUITING
ADCCBiologicNovartis PharmaceuticalsdeliveryPhase 3

Trametinib (Trametinib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 100%임상시험 79상태 DISCONTINUED
AntibodyCJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#인기#항체+5
임상시험 78상태 RECRUITING
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan (T-DXd) with pyrotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Approved#인기#항체약물접합체+4
효능 ORR 65.8%임상시험 78상태 RECRUITING
ADCCBiologicEli Lilly and CompanyPhase 2

Abemaciclib (Abemaciclib)

Advanced Cancer; Metastatic Melanoma · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 32.9%임상시험 77상태 RECRUITING
CGTABiologicJanssen Research & Development,…Phase 3

AA (Abiraterone acetate, Abiraterone acetate (AA))

Metastatic Castration-sensitive Prostate Cancer · Metastatic Castration-sensitive Prostate

#MetastaticCastration-sensitivePr#CGT#Phase3#인기#세포유전치료+3
효능 ORR 57.1%임상시험 77상태 RECRUITING
ADCABiologicEpizyme, Inc.Phase 2

Acalabrutinib (Acalabrutinib)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 82.4%임상시험 77상태 RECRUITING
ADCCBiologicHoffmann-La RochePhase 2

Cobimetinib (Cobimetinib)

Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 67.6%임상시험 77상태 DISCONTINUED
ADCCBiologicRemeGenvedotin plus PD-1 blockade …Phase 3

RC48 (Disitamab Vedotin, Disitamab Vedotin (RC48))

HER2 + Breast Cancer · mCRPC

#mCRPC#ADC#Phase3#인기#항체약물접합체+5
임상시험 76상태 RECRUITING
ADCBBiologicAmgensPhase 3

Sunitinib (Sunitinib)

Advanced Solid Tumors · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 78%임상시험 76상태 RECRUITING

7 / 209 페이지

← 이전다음 →